SHANGHAI
and BEIJING and HONG
KONG, Jan. 25, 2021
/PRNewswire/ -- Qiming Venture Partners ("Qiming") today
announced the final close of our RMB Fund VI at RMB 2.852 billion.
Currently, Qiming has $5.9 billion
in assets under management, targeting early-and-growth-stage
healthcare and TMT investments. Qiming raised our first RMB fund in
2010. For the past ten years, Qiming has demonstrated its ability
to deliver consistent distinguished returns for LPs and has been
well recognized by RMB fund investors.
Since our inception in 2006, Qiming has invested in more than
380 companies, among which over 40 achieved unicorn status. We have
exited our investments in over 130 companies through IPO, M&A
or other means. Notable exit deals include Xiaomi, Gan & Lee
Pharmaceuticals, Meituan, Bilibili, RoboRock, TigerMed,
Zai Lab, CanSino Biologics Inc.,
Venus Medtech, APT Medical, and so forth.
"Qiming has backed hundreds of brilliant entrepreneurs. We are
pleased to see that those companies are committed to social good,"
said Duane Kuang, Founding Managing
Partner of Qiming Venture Partners, "Qiming managed to close
both RMB and USD funds in the past five months, showing that LPs
are optimistic about our investment strategy to invest in
China's innovative and developing
science and technology, even during the challenging global COVID-19
epidemic as well as facing changing global environments."
In 2020, Qiming made over 70 investments; over 100 of our
existing portfolio companies completed new financing rounds.
As of today, we have had 13 successful public listings in our
portfolio since 2020. Over 60 of our invested companies contributed
to the fight against COVID-19 in China and for the global community.
"Innovation is the key for startups to break through and become
leaders. In the past ten years, we have seen lots of Chinese
entrepreneurs starting their business and striving to become a
global leader in innovation," said William
Hu, Managing Partner of Qiming Venture Partners. "The
closing of our new funds will enable us to support more visionary
founders realizing their entrepreneurial dreams."
About Qiming Venture Partners
Founded in 2006, Qiming Venture Partners is a leading
China venture capital firm with
offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong
Kong, Seattle, Boston and the San
Francisco Bay Area.
Currently Qiming Venture Partners manages nine US Dollar funds and six RMB funds with $5.9
billion in assets under management. Since our establishment,
we have invested in outstanding companies in the TMT and healthcare
industries at the early and growth stages.
Since our debut, we have backed over 380 fast-growing and
innovative companies. Over 130 companies are already listed on
NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock
Exchange and Shenzhen Stock Exchange, or achieved exit through
M&A and other means. There are also over 40 portfolio companies
that have achieved unicorn status.
Many of our portfolio companies are today's most influential
firms in their respective sectors, including Xiaomi (SEHK:1810),
Meituan (SEHK:3690), Bilibili (NASDAQ:BILI), Roborock
(SHSE:688169), Gan & Lee Pharmaceuticals (SHSE: 603087),
Tigermed (SZSE:300347, SEHK:3347), Zai
Lab (NASDAQ:ZLAB, SEHK:9688), Venus MedTech (SEHK:2500),
CanSino Biologics (SEHK:6185, SHSE:688185), Schrödinger
(NASDAQ:SDGR), APT Medical (SHSE:688617), Sanyou Medical
(SHSE:688085), AmoyDx (SZSE:300685), Berry Genomics (SZSE:000710),
SinocellTech (SHSE: 688520), WeDoctor Group, and UBTech among many
others.
View original
content:http://www.prnewswire.com/news-releases/qiming-venture-partners-closes-rmb-fund-vi-at-rmb-2-852-billion-301214577.html
SOURCE Qiming Venture Partners